Edition:
United Kingdom

Cara Therapeutics Inc (CARA.OQ)

CARA.OQ on NASDAQ Stock Exchange Global Market

25.86USD
22 Jul 2019
Change (% chg)

$-0.05 (-0.19%)
Prev Close
$25.91
Open
$26.18
Day's High
$26.49
Day's Low
$25.30
Volume
275,242
Avg. Vol
232,169
52-wk High
$27.50
52-wk Low
$12.20

Latest Key Developments (Source: Significant Developments)

Cara Therapeutics Results From Phase 3 Trial Of Korsuva In Hemodialysis Patients With Pruritus
Wednesday, 29 May 2019 

May 29 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM KALM-1 PIVOTAL PHASE 3 TRIAL OF KORSUVA™ INJECTION IN HEMODIALYSIS PATIENTS WITH PRURITUS.CARA THERAPEUTICS INC - STATISTICALLY SIGNIFICANT IMPROVEMENT IN PRIMARY ENDPOINT.CARA THERAPEUTICS INC - KORSUVA INJECTION WELL-TOLERATED THROUGH 12 WEEKS OF TREATMENT.CARA THERAPEUTICS INC - KORSUVA INJECTION WELL-TOLERATED THROUGH 12 WEEKS OF TREATMENT -.CARA THERAPEUTICS INC - KORSUVA INJECTION WELL-TOLERATED THROUGH 12 WEEKS OF TREATMENT.CARA THERAPEUTICS INC - KORSUVA INJECTION WELL-TOLERATED THROUGH 12 WEEKS OF TREATMENT.CARA THERAPEUTICS INC - OVERALL, INCIDENCE OF ADVERSE EVENTS & SERIOUS AES WERE SIMILAR ACROSS BOTH KORSUVA & PLACEBO GROUPS.CARA THERAPEUTICS INC - OVERALL, INCIDENCE OF ADVERSE EVENTS (AES) AND SERIOUS AES WERE SIMILAR ACROSS BOTH KORSUVA AND PLACEBO GROUPS.  Full Article

Cara Therapeutics Q3 Loss Per Share $0.51
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.51.Q3 EARNINGS PER SHARE VIEW $-0.50 -- THOMSON REUTERS I/B/E/S.RECOGNIZED $5.0 MILLION OF LICENSE AND MILESTONE FEE REVENUE DURING Q3 OF 2018.AT SEPTEMBER 30, 2018, CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $206.1 MILLION.  Full Article

Cara Therapeutics And Vifor Fresenius Medical Care Renal Pharma Enter Into Ex-U.S. Licensing Agreement
Wednesday, 23 May 2018 

May 23 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS AND VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA (VFMCRP) ENTER INTO EX-U.S. LICENSING AGREEMENT TO COMMERCIALIZE KORSUVA™ INJECTION IN DIALYSIS PATIENTS WITH PRURITUS.CARA THERAPEUTICS INC - CARA ELIGIBLE FOR UP TO $470 MILLION IN REGULATORY AND COMMERCIAL MILESTONES.CARA THERAPEUTICS INC - VFMCRP TO COMMERCIALIZE KORSUVA INJECTION WORLDWIDE EXCEPT IN U.S., JAPAN AND SOUTH KOREA.CARA THERAPEUTICS INC - CARA RECEIVES UPFRONT PAYMENT OF $50 MILLION IN CASH AND AN EQUITY INVESTMENT OF $20 MILLION.CARA THERAPEUTICS INC - CARA IS ELIGIBLE TO RECEIVE TIERED ROYALTIES BASED ON NET SALES OF KORSUVA INJECTION IN LICENSED TERRITORIES.CARA THERAPEUTICS INC - CARA WILL SOLELY PROMOTE KORSUVA INJECTION IN ALL NON-FMC CLINICS IN U.S. AND RETAIN ALL PROFITS FROM THOSE SALES.  Full Article

Cara Therapeutics Reports Q4 Loss Per Share $0.43
Thursday, 15 Mar 2018 

March 15 (Reuters) - Cara Therapeutics Inc ::CARA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.43.Q4 EARNINGS PER SHARE VIEW $-0.40 -- THOMSON REUTERS I/B/E/S.‍COMPANY DID NOT RECOGNIZE ANY REVENUES DURING Q4 OF 2017 OR 2016​.  Full Article

Cara Therapeutics Inc reports Q3 loss per share $0.38
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Cara Therapeutics Inc :Cara Therapeutics Inc reports third quarter 2017 financial results.Q3 loss per share $0.38.Q3 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Cara Therapeutics Inc - expects existing cash and cash equivalents, among others to be sufficient to fund operating expenses, capex requirements into 2019​.  Full Article

Cara Therapeutics Q2 loss per share $0.29
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - Cara Therapeutics Inc ::Cara Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.29.Q2 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.Cara-‍ expects existing cash, cash equivalents, available-for-sale marketable securities to be sufficient to fund operating expenses, capex requirements into 2019​.  Full Article